Substituted aryl 1 ,2,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators

ABSTRACT

The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

RELATED APPLICATION

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/709,860, filed Oct. 4, 2012, the disclosure of which is hereby incorporated in its entirety herein by reference.

FIELD OF THE INVENTION

The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate (S1P) receptor modulation.

BACKGROUND OF THE INVENTION

Sphingosine-1 phosphate is stored in relatively high concentrations in human platelets, which lack the enzymes responsible for its catabolism, and it is released into the blood stream upon activation of physiological stimuli, such as growth factors, cytokines, and receptor agonists and antigens. It may also have a critical role in platelet aggregation and thrombosis and could aggravate cardiovascular diseases. On the other hand the relatively high concentration of the metabolite in high-density lipoproteins (HDL) may have beneficial implications for atherogenesis. For example, there are recent suggestions that sphingosine-1-phosphate, together with other lysolipids such as sphingosylphosphorylcholine and lysosulfatide, are responsible for the beneficial clinical effects of HDL by stimulating the production of the potent antiatherogenic signaling molecule nitric oxide by the vascular endothelium. In addition, like lysophosphatidic acid, it is a marker for certain types of cancer, and there is evidence that its role in cell division or proliferation may have an influence on the development of cancers. These are currently topics that are attracting great interest amongst medical researchers, and the potential for therapeutic intervention in sphingosine-1-phosphate metabolism is under active investigation.

SUMMARY OF THE INVENTION

We have now discovered a group of novel compounds which are potent and selective sphingosine-1-phosphate modulators. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. The term “modulator” as used herein, includes but is not limited to: receptor agonist, antagonist, inverse agonist, inverse antagonist, partial agonist, partial antagonist.

This invention describes compounds of Formula I, which have sphingosine-1-phosphate receptor biological activity. The compounds in accordance with the present invention are thus of use in medicine, for example in the treatment of humans with diseases and conditions that are alleviated by S1P modulation.

In one aspect, the invention provides a compound having Formula I or a pharmaceutically acceptable salt thereof or individual enantiomers, diastereoisomers, tautomers, zwitterions and pharmaceutically acceptable salts thereof:

wherein: R¹ is substituted or unsubstituted C₆₋₁₀ aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted C₅₋₈ cycloalkyl, substituted or unsubstituted C₅₋₈ cycloalkenyl or hydrogen; R² is hydrogen, —OC₁₋₃ alkyl or substituted or unsubstituted C₁₋₃ alkyl; R³ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁹ or hydroxyl; R⁴ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁹ or hydroxyl; R⁵ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁹, hydroxyl or substituted or unsubstituted heterocycle; R⁶ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁹, hydroxyl or substituted or unsubstituted heterocycle; R⁷ is hydrogen, —OC₁₋₃ alkyl or substituted or unsubstituted C₁₋₃ alkyl; R⁸ is H or C₁₋₃ alkyl; R⁹ is OPO₃H₂, carboxylic acid, PO₃H₂, —P(O)MeOH, —P(O)(H)OH or OR¹⁹; R¹⁰ is H or C₁₋₃ alkyl; a is 2 or 3; b is 1, 2 or 3; c is 1, 2, 3, 4, 5 or 6; with the proviso that the compound of Formula I is not of structures

The term “alkyl”, as used herein, refers to saturated, monovalent or divalent hydrocarbon moieties having linear or branched moieties or combinations thereof and containing 1 to 3 carbon atoms. One methylene (—CH₂—) group, of the alkyl can be replaced by oxygen, sulfur, sulfoxide, —NH—, carbonyl, carboxyl, sulfonyl, or by a divalent C₃₋₆ cycloalkyl. Alkyl groups can be substituted by halogen, hydroxyl, cycloalkyl, amino, non-aromatic heterocycles, carboxylic acid, phosphonic acid groups, sulphonic acid groups, phosphoric acid.

The term “cycloalkyl”, as used herein, refers to a monovalent or divalent group of 5 to 8 carbon atoms derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be monocyclic or polycyclic. Cycloalkyl can be substituted by 1 to 3 C₁₋₃ alkyl groups or 1 or 2 halogens.

The term “cycloalkenyl”, as used herein, refers to a monovalent or divalent group of 5 to 8 carbon atoms derived from a saturated cycloalkyl having one double bond. Cycloalkenyl groups can be monocyclic or polycyclic. Cycloalkenyl groups can be substituted by 1 to 3 C₁₋₃ alkyl groups or 1 or 2 halogens.

The term “halogen”, as used herein, refers to an atom of chlorine, bromine, fluorine, iodine.

The term “heterocycle” as used herein, refers to a 3 to 10 membered ring, which can be aromatic or non-aromatic, saturated or non-saturated, containing at least one heteroatom selected form O or N or S or combinations of at least two thereof, interrupting the carbocyclic ring structure. The heterocyclic ring can be saturated or non-saturated. The heterocyclic ring can be interrupted by a C═O; the S heteroatom can be oxidized. Heterocycles can be monocyclic or polycyclic. Heterocyclic ring moieties can be substituted by hydroxyl, 1 to 2 C₁₋₃ alkyl or 1 to 2 halogens.

The term “aryl” as used herein, refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring containing 6 to 10 carbon atoms by removal of one hydrogen, which can be substituted by 1 to 3 halogen atoms or by 1 to 2 C₁₋₃ alkyl groups.

The term “hydroxyl” as used herein, represents a group of formula “—OH”.

The term “carbonyl” as used herein, represents a group of formula “—C(O)”.

The term “carboxyl” as used herein, represents a group of formula “—C(O)O—”.

The term “sulfonyl” as used herein, represents a group of formula “—SO₂”.

The term “sulfate” as used herein, represents a group of formula “—O—S(O)₂—O—”.

The term “carboxylic acid” as used herein, represents a group of formula “—C(O)ON”.

The term “sulfoxide” as used herein, represents a group of formula “—S═O”.

The term “phosphonic acid” as used herein, represents a group of formula “—P(O)(OH)₂”.

The term “phosphoric acid” as used herein, represents a group of formula “—(O)P(O)(OH)₂”.

The term “sulphonic acid” as used herein, represents a group of formula “—S(O)₂OH”.

The formula “H”, as used herein, represents a hydrogen atom.

The formula “O”, as used herein, represents an oxygen atom.

The formula “N”, as used herein, represents a nitrogen atom.

The formula “S”, as used herein, represents a sulfur atom.

Compounds of the invention are:

-   [3-({3-(Furan-2-yl)-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)     propyl]phosphonic acid; -   [3-({3-Bromo-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)     propyl]phosphonic acid; -   [3-({3-Fluoro-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic     acid; -   [3-({4-[5-(5-Phenylpentyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic     acid; -   [3-({4-[5-(3-Phenylpropyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic     acid; -   3-({4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propanoic     acid; -   [3-({4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic     acid; -   [3-({2-Ethyl-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic     acid.

Some compounds of Formula I and some of their intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in an R or S configuration, said R and S notation is used in correspondence with the rules described in Pure Appli. Chem. (1976), 45, 11-13.

The term “pharmaceutically acceptable salts” refers to salts or complexes that retain the desired biological activity of the above identified compounds and exhibit minimal or no undesired toxicological effects. The “pharmaceutically acceptable salts” according to the invention include therapeutically active, non-toxic base or acid salt forms, which the compounds of Formula I are able to form.

The acid addition salt form of a compound of Formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, such as for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; or an organic acid such as for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric, methylsulfonic, ethanesulfonic, benzenesulfonic, formic and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahal & Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta-Zürich, 2002, 329-345).

The base addition salt form of a compound of Formula I that occurs in its acid form can be obtained by treating the acid with an appropriate base such as an inorganic base, for example, sodium hydroxide, magnesium hydroxide, potassium hydroxide, calcium hydroxide, ammonia and the like; or an organic base such as for example, L-Arginine, ethanolamine, betaine, benzathine, morpholine and the like. (Handbook of Pharmaceutical Salts, P. Heinrich Stahal& Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta-Zurich, 2002, 329-345).

The compounds of the invention are indicated for use in treating or preventing conditions in which there is likely to be a component involving the sphingosine-1-phosphate receptors.

In another embodiment, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier. In a further embodiment of the invention, there are provided methods for treating disorders associated with modulation of sphingosine-1-phosphate receptors. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one compound of the invention.

These compounds are useful for the treatment of mammals, including humans, with a range of conditions and diseases that are alleviated by S1P modulation: not limited to the treatment of diabetic retinopathy, other retinal degenerative conditions, dry eye, angiogenesis and wounds.

Therapeutic utilities of S1P modulators are ocular diseases, such as but not limited to: wet and dry age-related macular degeneration, diabetic retinopathy, angiogenesis inhibition, retinopathy of prematurity, retinal edema, geographic atrophy, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation-induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases such as but not limited to: various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression such as but not limited to: rheumatoid arthritis, Crohn's disease, Graves' disease, inflammatory bowel disease, multiple sclerosis, Myasthenia gravis, Psoriasis, ulcerative colitis, antoimmune uveitis, renal ischemia/perfusion injury, contact hypersensitivity, atopic dermititis, and organ transplantation; or allergies and other inflammatory diseases such as but not limited to: urticaria, bronchial asthma, and other airway inflammations including pulmonary emphysema and chronic obstructive pulmonary diseases; or cardiac protection such as but not limited to: ischemia reperfusion injury and atherosclerosis; or wound healing such as but not limited to: scar-free healing of wounds from cosmetic skin surgery, ocular surgery, GI surgery, general surgery, oral injuries, various mechanical, heat and burn injuries, prevention and treatment of photoaging and skin ageing, and prevention of radiation-induced injuries; or bone formation such as but not limited to: treatment of osteoporosis and various bone fractures including hip and ankles; or anti-nociceptive activity such as but not limited to: visceral pain, pain associated with diabetic neuropathy, rheumatoid arthritis, chronic knee and joint pain, tendonitis, osteoarthritis, neuropathic pains; or central nervous system neuronal activity in Alzheimer's disease, age-related neuronal injuries; or in organ transplant such as renal, corneal, cardiac or adipose tissue transplant.

In still another embodiment of the invention, there are provided methods for treating disorders associated with modulation of sphingosine-1-phosphate receptors. Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of at least one compound of the invention, or any combination thereof, or pharmaceutically acceptable salts, individual enantiomers, and diastereomers thereof.

The present invention concerns the use of a compound of Formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of ocular disease, wet and dry age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, retinal edema, geographic atrophy, angiogenesis inhibition, glaucomatous optic neuropathy, chorioretinopathy, hypertensive retinopathy, ocular ischemic syndrome, prevention of inflammation-induced fibrosis in the back of the eye, various ocular inflammatory diseases including uveitis, scleritis, keratitis, and retinal vasculitis; or systemic vascular barrier related diseases, various inflammatory diseases, including acute lung injury, its prevention, sepsis, tumor metastasis, atherosclerosis, pulmonary edemas, and ventilation-induced lung injury; or autoimmune diseases and immunosuppression, rheumatoid arthritis, Crohn's disease, Graves' disease, inflammatory bowel disease, multiple sclerosis, Myasthenia gravis, Psoriasis, ulcerative colitis, antoimmune uveitis, renal ischemia/perfusion injury, contact hypersensitivity, atopic dermititis, and organ transplantation; or allergies and other inflammatory diseases, urticaria, bronchial asthma, and other airway inflammations including pulmonary emphysema and chronic obstructive pulmonary diseases; or cardiac protection, ischemia reperfusion injury and atherosclerosis; or wound healing, scar-free healing of wounds from cosmetic skin surgery, ocular surgery, GI surgery, general surgery, oral injuries, various mechanical, heat and burn injuries, prevention and treatment of photoaging and skin ageing, and prevention of radiation-induced injuries; or bone formation, treatment of osteoporosis and various bone fractures including hip and ankles; or anti-nociceptive activity, visceral pain, pain associated with diabetic neuropathy, rheumatoid arthritis, chronic knee and joint pain, tendonitis, osteoarthritis, neuropathic pains; or central nervous system neuronal activity in Alzheimer's disease, age-related neuronal injuries; or in organ transplant such as renal, corneal, cardiac or adipose tissue transplant.

The actual amount of the compound to be administered in any given case will be determined by a physician taking into account the relevant circumstances, such as the severity of the condition, the age and weight of the patient, the patient's general physical condition, the cause of the condition, and the route of administration.

The patient will be administered the compound orally in any acceptable form, such as a tablet, liquid, capsule, powder and the like, or other routes may be desirable or necessary, particularly if the patient suffers from nausea. Such other routes may include, without exception, transdermal, parenteral, subcutaneous, intranasal, via an implant stent, intrathecal, intravitreal, topical to the eye, back to the eye, intramuscular, intravenous, and intrarectal modes of delivery. Additionally, the formulations may be designed to delay release of the active compound over a given period of time, or to carefully control the amount of drug released at a given time during the course of therapy.

In another embodiment of the invention, there are provided pharmaceutical compositions including at least one compound of the invention in a pharmaceutically acceptable carrier thereof. The phrase “pharmaceutically acceptable” means the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical compositions of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a patch, a micelle, a liposome, and the like, wherein the resulting composition contains one or more compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Invention compounds may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. Invention compounds are included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or disease condition.

Pharmaceutical compositions containing invention compounds may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of a sweetening agent such as sucrose, lactose, or saccharin, flavoring agents such as peppermint, oil of wintergreen or cherry, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets containing invention compounds in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.

In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the invention compounds are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the invention compounds are mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

The pharmaceutical compositions may be in the form of a sterile injectable suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

Pharmaceutical compositions containing invention compounds may be in a form suitable for topical use, for example, as oily suspensions, as solutions or suspensions in aqueous liquids or nonaqueous liquids, or as oil-in-water or water-in-oil liquid emulsions. Pharmaceutical compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable salt thereof, as an active ingredient with conventional ophthalmically acceptable pharmaceutical excipients and by preparation of unit dosage suitable for topical ocular use. The therapeutically efficient amount typically is between about 0.0001 and about 5% (w/v), preferably about 0.001 to about 2.0% (w/v) in liquid formulations.

For ophthalmic application, preferably solutions are prepared using a physiological saline solution as a major vehicle. The pH of such ophthalmic solutions should preferably be maintained between 4.5 and 8.0 with an appropriate buffer system, a neutral pH being preferred but not essential. The formulations may also contain conventional pharmaceutically acceptable preservatives, stabilizers and surfactants. Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate. A preferred surfactant is, for example, Tween 80. Likewise, various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose cyclodextrin and purified water.

Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.

Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.

In a similar manner an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene. Other excipient components which may be included in the ophthalmic preparations are chelating agents. The preferred chelating agent is edentate disodium, although other chelating agents may also be used in place of or in conjunction with it.

The ingredients are usually used in the following amounts:

Ingredient Amount (% w/v)

active ingredient about 0.001-5

preservative 0-0.10

vehicle 0-40

tonicity adjustor 0-10

buffer 0.01-10

pH adjustor q.s. pH 4.5-7.8

antioxidant as needed

surfactant as needed

purified water to make 100%

The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

The ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate application to the eye. Containers suitable for drop wise application are usually made of suitable inert, non-toxic plastic material, and generally contain between about 0.5 and about 15 ml solution. One package may contain one or more unit doses.

Especially preservative-free solutions are often formulated in non-resalable containers containing up to about ten, preferably up to about five units doses, where a typical unit dose is from one to about 8 drops, preferably one to about 3 drops. The volume of one drop usually is about 20-35 ml.

Invention compounds may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the invention compounds with a suitable non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

Since individual subjects may present a wide variation in severity of symptoms and each drug has its unique therapeutic characteristics, the precise mode of administration and dosage employed for each subject is left to the discretion of the practitioner.

The compounds and pharmaceutical compositions described herein are useful as medicaments in mammals, including humans, for treatment of diseases and/or alleviations of conditions which are responsive to treatment by agonists or functional antagonists of sphingosine-1-phosphate receptors. Thus, in further embodiments of the invention, there are provided methods for treating a disorder associated with modulation of sphingosine-1-phosphate receptors. Such methods can be performed, for example, by administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of at least one invention compound. As used herein, the term “therapeutically effective amount” means the amount of the pharmaceutical composition that will elicit the biological or medical response of a subject in need thereof that is being sought by the researcher, veterinarian, medical doctor or other clinician. In some embodiments, the subject in need thereof is a mammal. In some embodiments, the mammal is human.

The present invention concerns also processes for preparing the compounds of Formula I. The compounds of Formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry. Synthetic Schemes 1 and 2 set forth below, illustrate how compounds according to the invention can be made.

An alcohol, which could be obtained from the corresponding aldehyde, was treated with pyridinium p-toluenesulfonate and 3,4-dihydro-2H-pyran and stirred at RT for 16 h. The reaction mixture was diluted with water, extracted with methylene chloride, dried with magnesium sulfate and concentrated. After purification the intermediate was treated with sodium cyanide, palladium (II), TMEDA then 1,5-dis(diphenylphosphino)pentane in mesitylene was bubbled with argon for 10 min. The degassed reaction mixture was heated to 170° C. for 16 h. After cooling to RT, the reaction mixture was diluted with water, stirred for another 10 min then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate, concentrated and purified by MPLC to yield the corresponding benzonitrile intermediate.

To a solution of the benzonitrile intermediate in methanol was added hydroxylamine hydrochloride. After heating to 50° C. with stirring for 16 h, the reaction mixture was cooled to RT and concentrated to afford the corresponding N-hydroxy-4-(hydroxymethyl)benz-imidamide derivative.

To a solution of a carboxylic acid in THF at RT was added CDI. After stirring the reaction mixture for 2 h, a N-hydroxy-4-(hydroxymethyl)benz-imidamide derivative was added. After stirring at 50° C. for 3 h, the reaction mixture was then transferred to a microwave vial and heated at 150° C. for 20 minutes. After cooling to room temperature the mixture was diluted with water and extracted with ethyl acetate. The ethyl acetate phase was washed with water and brine, dried over sodium sulfate and concentrated. Purification of the residue by MPLC (40% ethyl acetate in hexanes) gave the corresponding oxadiazol intermediate. To the oxadiazol intermediate in dichloromethane and acetonitrile were added 4 Å molecular sieves, powdered NMO, TPAP. After stirring for 16 h, the reaction mixture was applied directly to a short silica gel plug followed by MPLC purification (20% ethyl acetate in hexanes) to afford the corresponding aldehyde.

The aldehyde intermediate was dissolved in methanol and 3-aminophosphonic acid was added. After the reaction mixture was stirred at RT for 1.5 h, tetrabutylammonium hydroxide was added. After the mixture was stirred at RT for 3.5 h, the mixture was concentrated and purified by MPLC (0-100% methanol in ethyl acetate) to give the desired compound of Formula I.

Those skilled in the art will be able to routinely modify and/or adapt Schemes 1 and 2 to synthesize any compound of the invention covered by Formula I.

The following abbreviations are used in the general schemes and in the examples:

CDI 1,1′-Carbonyldiimidazole

NaBH₄ Sodium borohydride

DHP Dihydropyran

CH₂Cl₂ Dichloromethane

NaCN Sodium cyanide

Pd(OAc)₂ Palladium(II) acetate

TMEDA Tetramethylethylenediamine

Ph₂P(CH₂)₅PPh₂ 1,5-Bis(diphenylphosphino)pentane

NH₂OH Hydroxylamine

Bu₄NOH tetra-Butylammonium hydroxide

MWI Microwave

THF Tetrahydrofuran

NMO N-Methylmorpholine-N-Oxide

TPAP Tetrapropylammonium perruthenate

MPLC Medium pressure liquid chromatography

MeOH Methanol

RT Room temperature

CDCl₃ Deuterated chloroform

CD₃OD Deuterated methanol

PPTS Pyridine p-toluenesulfonate

DETAILED DESCRIPTION OF THE INVENTION

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention claimed. As used herein, the use of the singular includes the plural unless specifically stated otherwise.

It will be readily apparent to those skilled in the art that some of the compounds of the invention may contain one or more asymmetric centers, such that the compounds may exist in enantiomeric as well as in diastereomeric forms. Unless it is specifically noted otherwise, the scope of the present invention includes all enantiomers, diastereomers and racemic mixtures. Some of the compounds of the invention may form salts with pharmaceutically acceptable acids or bases, and such pharmaceutically acceptable salts of the compounds described herein are also within the scope of the invention.

The present invention includes all pharmaceutically acceptable isotopically enriched compounds. Any compound of the invention may contain one or more isotopic atoms enriched or different than the natural ratio such as deuterium ²H (or D) in place of protium ¹H (or H) or use of ¹³ C enriched material in place of ¹²C and the like. Similar substitutions can be employed for N, O and S. The use of isotopes may assist in analytical as well as therapeutic aspects of the invention. For example, use of deuterium may increase the in vivo half-life by altering the metabolism (rate) of the compounds of the invention. These compounds can be prepared in accord with the preparations described by use of isotopically enriched reagents.

The following examples are for illustrative purposes only and are not intended, nor should they be construed as limiting the invention in any manner. Those skilled in the art will appreciate that variations and modifications of the following examples can be made without exceeding the spirit or scope of the invention.

As will be evident to those skilled in the art, individual diasteroisomeric forms can be obtained by separation of mixtures thereof in conventional manner, chromatographic separation may be employed.

Compound names were generated with ACDLabs version 12.5 and intermediates and reagent names used in the examples were generated with software such as Chem Bio Draw Ultra version 12.0 or Auto Nom 2000 from MDL ISIS Draw 2.5 SP1.

In general, characterization of the compounds is performed according to the following methods, NMR spectra are recorded on 300 and/or 600 MHz Varian and acquired at room temperature. Chemical shifts are given in ppm referenced either to internal TMS or to the solvent signal.

All the reagents, solvents, catalysts for which the synthesis is not described are purchased from chemical vendors such as Sigma Aldrich, Fluka, Bio-Blocks, Combi-blocks, TCI, VWR, Lancaster, Oakwood, Trans World Chemical, Alfa, Fisher, AK Scientific, AmFine Com, Carbocore, Maybridge, Frontier, Matrix, Ukrorgsynth, Toronto, Ryan Scientific, SiliCycle, Anaspec, Syn Chem, Chem-Impex, MIC-scientific, Ltd; however some known intermediates, were prepared according to published procedures.

Usually the compounds of the invention were purified by column chromatography (Auto-column) on an Teledyne-ISCO CombiFlash with a silica column, unless noted otherwise.

Example 1 Intermediate 1 2-[(4-Bromo-2-ethylbenzyl)oxy]tetrahydro-2H-pyran

To a solution of (4-bromo-2-ethylphenyl)methanol (CAS 877131-21-0) (2.8 g, 13 mmol) in methylene chloride (45 mL) were added pyridinium p-toluenesulfonate (327 mg, 1.3 mmol) and 3,4-dihydro-2H-pyran (2.4 mL, 26 mmol) and stirred at RT for 16 h. The reaction mixture was diluted with water, extracted with methylene chloride, dried with magnesium sulfate and concentrated. Purification by MPLC (30% ethyl acetate in hexanes) afforded 2.9 g of Intermediate 1 as a colorless oil.

¹H NMR (600 MHz, CDCl₃) δ ppm 7.34 (d, J=2.05 Hz, 1H), 7.31 (dd, J=2.93, 8.22 Hz, 1H), 7.25 (d, J=8.22 Hz, 1H), 4.75 (d, J=12.03 Hz, 1H), 4.69 (t, J=3.52 Hz, 1H), 4.45 (d, J=12.32 Hz, 1H), 3.89 (ddd, J=3.08, 8.66, 11.44 Hz, 1H), 3.53-3.57 (m, 1H), 2.66 (q, J=7.63 Hz, 2H), 1.81-1.89 (m, 1H), 1.70-1.76 (m, 1H), 1.51-1.66 (m, 4H), 1.22 (t, J=7.63 Hz, 3H)

Intermediate 2 was prepared from the corresponding starting material, in a similar manner to the procedure described in Example 1 for Intermediate 1. The results are tabulated below in Table 1.

TABLE 1 Interm IUPAC name No. Structure Starting material ¹H NMR δ (ppm) 2 2-Bromo-4- [(tetrahydro-2H-pyran- 2-yloxy) methyl]benzonitrile

2-bromo-4- (hydroxymethyl) - benzonitrile CAS 90110-97-7 ¹H NMR (600 MHz, CDCl₃) δ 7.70 (d, J = 0.88 Hz, 1H), 7.62 (d, J = 7.92 Hz, 1H), 7.39-7.41 (m, 1H), 4.81 (d, J = 13.79 Hz, 1H), 4.71 (t, J = 3.52 Hz, 1H), 4.53 (d, J = 13.50 Hz, 1H), 3.86 (ddd, J = 2.93, 8.80, 12.03 Hz, 1H), 3.56 (dtd, J = 1.61, 4.35, 11.11 Hz, 1H), 1.83- 1.91 (m, 1H), 1.75- 1.80 (m, 1H), 1.54-1.72 (m, 4H)

Example 2 Intermediate 3 2-(2-Furyl)-4-[(tetrahydro-2H-pyran-2-yloxy)methyl]benzonitrile

To a solution of Intermediate 2 (829 mg, 2.8 mmol) and 2-(tributylstannyl)furan (2.0 g, 5.6 mmol) in DMF(20 mL), in a microwave vial, was added bis(triphenylphosphine)palladium (II) dichloride (295 mg, 0.42 mmol). After submitting to microwave induction at 160° C. for 20 min, the reaction mixture was cooled to RT and quenched with saturated ammonium chloride aqueous solution. The mixture was extracted with ethyl acetate, followed by washing the combined organic layers with brine, dried over magnesium sulfate and concentrated. Purification by MPLC (1% ethyl acetate in hexanes) gave rise to 1.24 g of Intermediate 3 as a brown oil.

¹H NMR (600 MHz, CDCl₃) δ ppm 7.88 (d, J=0.88 Hz, 1H), 7.68 (d, J=8.22 Hz, 1H), 7.56 (dd, J=0.59, 1.76 Hz, 1H), 7.33-7.35 (m, 1H), 7.31 (dd, J=0.59, 3.52 Hz, 1H), 6.56 (dd, J=1.76, 3.52 Hz, 1H), 4.86 (d, J=13.21 Hz, 1H), 4.74 (t, J=3.52 Hz, 1H), 4.59 (d, J=13.20 Hz, 1H), 3.90 (ddd, J=3.08, 8.73, 11.37 Hz, 1H), 3.55-3.59 (m, 1H), 1.85-1.92 (m, 1H), 1.76-1.81 (m, 1H), 1.68-1.73 (m, 1H), 1.55-1.67 (m, 3H).

Example 3 Intermediate 4 3-Ethyl-4-[(tetrahydro-2H-pyran-2-yloxy)methyl]benzonitrile

A solution of Intermediate 1 (2.9 g, 9.7 mmol), sodium cyanide (950 mg, 19.4 mmol), palladium (II) acetate (109 mg, 0.49 mmol), TMEDA (2.2 mL, 14.9 mmol), and 1,5-dis(diphenylphosphino)pentane (855 mg, 1.94 mmol) in mesitylene (50 mL) was bubbled with argon for 10 min. The degassed reaction mixture was heated to 170° C. for 16 h. After cooling to RT, the reaction mixture was diluted with water, stirred for another 10 min then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated. Purification by MPLC (40% ethyl acetate in hexanes) gave rise to 2.23 g of Intermediate 4 as colorless oil.

¹H NMR (600 MHz, CDCl₃) δ ppm 7.55 (d, J=7.92 Hz, 1H), 7.49 (s, 1H), 7.48 (s, 1H), 4.85 (d, J=13.20 Hz, 1H), 4.73 (t, J=3.52 Hz, 1H), 4.55 (d, J=13.20 Hz, 1H), 3.88 (ddd, J=3.23, 8.80, 11.44 Hz, 1H), 3.55-3.59 (m, 1H), 2.68 (q, J=7.63 Hz, 2H), 1.83-1.90 (m, 1H), 1.74-1.79 (m, 1H), 1.53-1.71 (m, 4H), 1.25 (t, J=7.63 Hz, 3H).

Example 4 Intermediate 5 2-Fluoro-N′-hydroxy-4-(hydroxymethyl)benzenecarboximidamide

To a solution of 2-fluoro-4-hydroxymethylbenzonitrile (CAS 222978-02-1) (2.5 g, 16.5 mmol) in methanol (30 mL) was added hydroxylamine hydrochloride (3 mL, 50 mmol). After heating to 50° C. with stirring for 16 h, the reaction mixture was cooled to RT and concentrated to afford 1.3 g of Intermediate 5.

¹H NMR (300 MHz, CD₃OD) δ ppm 7.49 (t, J=7.30 Hz, 1H), 7.18 (s, 1H), 7.15 (dd, J=0.73, 2.20 Hz, 1H), 4.62 (s, 2H).

Intermediates 6 through 8 were prepared from the corresponding starting materials, in a similar manner to the procedure described in Example 4 for Intermediate 5. The results are tabulated below in Table 2.

TABLE 2 Interm IUPAC name No. Structure Starting material ¹H NMR δ (ppm) 6 2-Bromo-N′-hydroxy- 4-(hydroxylmethyl) benzenecarboximidamide

2-Bromo-4- (hydroxymethyl)- benzonitrile CAS 90110-97-7 ¹H NMR (300 MHz, CD₃OD) δ 7.63 (d, J = 0.59 Hz, 1H), 7.33-7.39 (m, 2H), 4.60 (s, 2H) 7 2-(2-Furyl)-N′- hydroxy-4- [(tetrahydro-2H-pyran- 2-yloxy)methyl] benzenecarboximidamide

Intermediate 3 ¹H NMR (600 MHz, CDCl₃) δ 7.75 (d, J = 1.47 Hz, 1H), 7.49 (dd, J = 0.88, 1.76 Hz, 1H), 7.44 (d, J = 7.63 Hz, 1H), 7.32 (dd, J = 1.61, 7.78 Hz, 1H), 6.72 (dd, J = 0.73, 3.37 Hz, 1H), 6.46 (dd, J = 1.76, 3.52 Hz, 1H), 4.82 (d, J = 12.32 Hz, 1H), 4.71-4.74 (m, 3H), 4.56 (d, J = 12.62 Hz, 1H), 3.92 (ddd, J = 3.08, 8.51, 11.30 Hz, 1H), 3.54- 3.58 (m, 1H), 1.85- 1.91 (m, 1H), 1.73-1.78 (m, 1H), 1.59-1.70 (m, 2H), 1.52-1.58 (m, 2H) 8 3-Ethyl-N′-hydroxy-4- [(tetrahydro-2H-pyran- 2-yloxy)methyl] benzenecarboximidamide

Intermediate 4 ¹H NMR (600 MHz, CDCl₃) δ 7.49 (s, 1H), 7.44 (s, 1H), 7.44 (s, 1H), 4.89 (br. s., 1H), 4.83 (d, J = 12.32 Hz, 1H), 4.72 (t, J = 3.52 Hz, 1H), 4.53 (d, J = 12.32 Hz, 1H), 4.09-4.15 (m, J = 7.00, 7.00, 7.00 Hz, 1H), 3.91 (ddd, J = 2.79, 8.66, 11.44 Hz, 1H), 3.55- 3.59 (m, 1H), 2.71 (q, J = 7.53 Hz, 2H), 1.83-1.90 (m, 1H), 1.72-1.77 (m, 1H), 1.59-1.68 (m, 2H), 1.52-1.58 (m, 2H), 1.24 (t, J = 7.60 Hz, 3H)

Example 5 Intermediate 9 3-{2-(2-Furyl)-4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenyl}-5-(4-phenylbutyl)-1,2,4-oxadiazole

To a solution of 5-phenylpentanoic acid (CAS 2270-20-4) (908 mg, 5.1 mmol) in THF (20 mL) at RT was added 1,1′-carbonyldiimidazole (827 mg, 5.1 mmol). After stirring the reaction mixture for 2 h, Intermediate 7 (1.61 g, 5.1 mmol) was added. After stirring at 50° C. for 3 h, the reaction mixture was then transferred to a microwave vial and heated at 150° C. for 20 minutes. After cooling to room temperature the mixture was diluted with water and extracted with ethyl acetate. Ethyl acetate phase was washed with water and brine, dried over sodium sulfate and concentrated. Purification of the residue by MPLC (25% ethyl acetate in hexanes) gave 1.02 g of Intermediate 9 as colorless oil.

¹H NMR (600 MHz, CDCl₃) δ ppm 7.70 (d, J=1.17 Hz, 1H), 7.63 (d, J=7.63 Hz, 1H), 7.41 (dd, J=1.76, 7.92 Hz, 1H), 7.26-7.31 (m, 3H), 7.16-7.20 (m, 3H), 6.34-6.36 (m, 2H), 4.86 (d, J=12.62 Hz, 1H), 4.73 (t, J=3.52 Hz, 1H), 4.60 (d, J=12.62 Hz, 1H), 3.92 (ddd, J=3.08, 8.51, 11.30 Hz, 1H), 3.54-3.58 (m, 1H), 2.93 (t, J=7.48 Hz, 2H), 2.66 (t, J=7.63 Hz, 2H), 1.84-1.91 (m, 3H), 1.67-1.79 (m, 4H), 1.54-1.63 (m, 3H).

Intermediates 10 through 15 were prepared from the corresponding starting materials, in a similar manner to the procedure described in Example 5 for Intermediate 9. The results are tabulated below in Table 3.

TABLE 3 Interm IUPAC name No. Structure Starting material ¹H NMR δ (ppm) 10 3-{3-Ethyl-4-[(tetrahydro- 2H-pyran-2- yloxy)methyl]phenyl}-5- (4-phenylbutyl)-1,2,4- oxadiazole

5-phenyl pentanoic acid CAS 2270-20-4 Intermediate 8 ¹H NMR (600 MHz, CDCl₃) δ 7.92 (s, 1H), 7.90 (d, J = 8.22 Hz, 1H), 7.52 (d, J = 7.92 Hz, 1H), 7.25- 7.28 (m, 2H), 7.16- 7.19 (m, 3H), 4.86 (d, J = 12.62 Hz, 1H), 4.73 (t, J = 3.52 Hz, 1H), 4.56 (d, J = 12.32 Hz, 1H), 3.91 (ddd, J = 2.93, 8.66, 11.30 Hz, 1H), 3.54- 3.53 (m, 1H), 2.94 (t, J = 7.48 Hz, 2H), 2.74 (q, J = 7.43 Hz, 2H), 2.67 (t, J =7.78 Hz, 2H), 1.84-1.93 (m, 3H), 1.72-1.78 (m, 3H), 1.52-1.70 (m, 4H), 1.28 (t, J = 7.63 Hz, 3H) 11 {3-Fluoro-4-[5-(4- phenylbutyl)-1,2,4- oxadiazol-3- yl]phenyl}methanol

5-phenyl pentanoic acid CAS 2270-20-4 Intermediate 5 ¹H NMR (600 MHz, CDCl₃) δ 8.01 (t, J = 7.78 Hz, 1H), 7.24- 7.30 (m, 4H), 7.17- 7.20 (m, 3H), 4.78 (s, 2H), 2.99 (t, J = 7.48 Hz, 2H), 2.69 (t, J = 7.63 Hz, 2H), 1.92 (quin, J = 7.90 Hz, 2H), 1.75- 1.80 (m, 2H) 12 {3-Bromo-4-[5-(4- phenylbutyl)-1,2,4- oxadiazol-3- yl]phenyl}methanol

5-phenyl pentanoic acid CAS 2270-20-4 Intermediate 6 ¹H NMR (600 MHz, CDCl₃) δ 7.71 (d, J = 7.92 Hz, 1H), 7.68 (d, J = 1.47 Hz, 1H), 7.32-7.34 (m, 1H), 7.25-7.29 (m, 2H), 7.16-7.20 (m, 3H), 4.69 (s, 2H), 2.99 (t, J =7.48 Hz, 2H), 2.68 (t, J = 7.63 Hz, 2H), (1.92 (dt, J = 7.63, 15.26 Hz, 2H), 1.74-1.80 (m, 2H) 13 {4-[5-(4-Phenylbutyl)- 1,2,4-oxadiazol-3- yl]phenyl}methanol

5-phenyl pentanoic acid CAS 2270-20-4 N-hydroxy-4- (hydroxymethyl) benzimidamide CAS 635702-23-7 ¹H NMR (600 MHz, CDCl₃) δ 8.01 (d, J = 8.22 Hz, 2H), 7.41 (d, J = 8.22 Hz, 2H), 7.26-7.31 (m, 2H), 7.17-7.21 (m, 3H), 4.68 (s, 2H), 2.92 (t, J = 7.63 Hz, 2H), 2.67 (t, J = 7.63 Hz, 2H), 1.89 (quin, J = 7.70 Hz, 2H), 1.75 (quin, J = 7.70 Hz, 2H) 14 {4-[5-(5-phenylpentyl)- 1,2,4-oxadiazol-3- yl]phenyl}methanol

6-phenylhexanoic acid CAS 5581-75-9 N-hydroxy-4- (hydroxymethyl) benzimidamide CAS 635702-23-7 ¹H NMR (600 MHz, CDCl₃) δ 8.02 (d, J = 8.22 Hz, 2H), 7.44 (d, J = 8.51 Hz, 2H), 7.25-7.28 (m, 2H), 7.15-7.18(m, 3H), 4.72 (s, 2H), 2.91 (t, J = 7.78 Hz, 2H), 2.62 (t, J = 7.78 Hz, 2H), 1.89 (quin, J = 7.63 Hz, 2H), 1.68 (quin, J = 7.70 Hz, 2H), 1.43-1.49 (m, 2H) 15 {4-[5-(3-phenylpropyl)- 1,2,4-oxadiazol-3- yl]phenyl}methanol

4-phenylbutanoic acid CAS 1716-12-7 N-hydroxy-4- (hydroxymethyl) benzimidamide CAS 635702-23-7 ¹H NMR (600 MHz, CDCl₃) δ 8.07 (d, J = 7.92 Hz, 2H), 7.48 (d, J = 8.22 Hz, 2H), 7.29-7.32 (m, 2H), 7.20-7.23 (m, 3H), 4.78 (s, 2H), 2.96 (t, J = 7.63 Hz, 2H), 2.78 (t, J = 7.48 Hz, 2H), 2.22 (quin, J = 7.56 Hz, 2H)

Example 6 Intermediate 16 {3-(2-Furyl)-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]phenyl}methanol

To a solution of Intermediate 9 (1.02 g, 2.2 mmol) in methanol (20 mL) was added PPTS (56 mg). After heating to 55° C. for 24 h, the reaction mixture was cooled to RT and concentrated. Purification by MPLC (30% ethyl acetate in hexanes) gave 621 mg of Intermediate 16 as a colorless oil.

¹H NMR (600 MHz, CDCl₃) δ ppm 7.69 (dd, J=0.59, 1.17 Hz, 1H), 7.61 (d, J=7.92 Hz, 1H), 7.37 (dd, J=1.47, 7.92 Hz, 1H), 7.27-7.30 (m, 3H), 7.16-7.21 (m, 3H), 6.34-6.35 (m, 2H), 4.77 (d, J=5.87 Hz, 2H), 2.94 (t, J=7.48 Hz, 2H), 2.66 (t, J=7.63 Hz, 2H), 1.84-1.90 (m, 2H), 1.70-1.75 (m, 2H).

Intermediate 17 was prepared from the corresponding intermediate, in a similar manner to the procedure described in Example 6 for Intermediate 16. The results are tabulated below in Table 4.

TABLE 4 Interm IUPAC name Starting No. Structure material ¹H NMR δ (ppm) 17 {2-Ethyl-4-[5-(4- phenylbutyl)-1,2,4- oxadiazol-3- yl]phenyl}methanol

Intermediate 10 ¹H NMR 600 MHz, CDCl₃) δ 7.89 (d, J = 1.47 Hz, 1 H), 7.87 (dd, J = 1.61, 7.78 Hz, 1H), 7.48 (d, J = 7.92 Hz, 1H), 7.26- 7.20 (m, 3H), 4.75 (s, 2H), 2.95 (t, J = 7.63 Hz, 2H), 2.69-2.76 (m, 2H), 2.67 (t, J = 7.63 Hz, 2H), 2.21 (br. s., 1H), 1.87- 1.93 (m, 2H), 1.73-1.78 (m, 2H), 1.26 (t, J = 7.63 Hz, 3H)

Example 7 Intermediate 18 3-Fluoro-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzaldehyde

To a solution of Intermediate 11 (302 mg, 0.97 mmol) in dichloromethane (10 mL) and acetonitrile (1.2 mL) were added 4 Å molecular sieves, powdered (0.5 g), 4-methylmorpholine N-oxide (285 mg, 2.4 mmol), tetrapropylammonium perruthenate (20 mg). After stirring for 16 h, the reaction mixture was applied directly to a short silica gel plug followed by MPLC purification (10% ethyl acetate in hexanes) to afford 136 mg Intermediate 18 as a colorless solid.

¹H NMR (300 MHz, CDCl₃) δ ppm 10.05 (d, J=1.47 Hz, 1H), 8.25 (dd, J=6.74, 7.91 Hz, 1H), 7.73 (dd, J=1.32, 10.11 Hz, 2H), 7.25-7.32 (m, 2H), 7.16-7.22 (m, 3H), 3.01 (t, J=7.47 Hz, 2H), 2.69 (t, J=7.47 Hz, 2H), 1.88-1.99 (m, 2H), 1.72-1.83 (m, 2H).

Intermediates 19 through 24 were prepared from the corresponding starting materials, in a similar manner to the procedure described in Example 7 for Intermediate 18. The results are tabulated below in Table 5.

TABLE 5 Interm IUPAC name Starting No. Structure material ¹H NMR δ (ppm) 19 3-Bromo-4-[5-(4- phenylbutyl)-1,2,4- oxadiazol-3- yl]benzaldehyde

Intermediate 12 ¹H NMR (300 MHz, CDCl₃) δ 10.02 (s, 1H), 8.21 (d, J = 1.17 Hz, 1H), 8.01 (d, J = 7.91 Hz, 1H), 7.91 (dd, J = 2.05, 7.91 Hz, 1H), 7.25-7.32 (m, 2H), 7.16-7.22 (m, 3H), 3.01 (t, J = 7.33 Hz, 2H), 2.69 (t, J = 7.47 Hz, 2H), 1.88- 1.99 (m, 2H), 1.73- 1.84 (m, 2H) 20 3-(2-Furyl)-4-[5-(4- phenylbutyl)-1,2,4- oxadiazol-3- yl]benzaldehyde

Intermediate 16 ¹H NMR (300 MHz, CDCl₃) δ 10.10 (s, 1H), 8.21 (d, J =1.47 Hz, 1H), 7.89 (66, J = 1.76, 7.91 Hz, 1H), 7.81 (d, J = 7.91 Hz, 1H), 7.34 (d, J = 1.76 Hz, 1H), 7.24-7.31 (m, 2H), 7.15-7.22 (m, 3H), 6.44 (d, J = 3.22 Hz, 1H), 6.38 (dd, J = 1.76, 3.52 Hz, 1H), 2.96 (t, J = 7.33 Hz, 2H), 2.66 (t, J = 7.62 Hz, 2H), 1.83-1.93 (m, 2H), 1.66-1.78 (m, 2H) 21 2-Ethyl-4-[5-(4- phenylbutyl)-1,2,4- oxadiazol-3- yl]benzaldehyde

Intermediate 17 ¹H NMR (600 MHz, CDCl₃) δ 10.35 (s, 1H), 8.06 (dd, J = 1.61, 8.07 Hz, 1H), 8.02 (d, J = 1.47 Hz, 1H), 7.94 (d, J = 7.92 Hz, 1H), 7.27-7.30 (m, 2H), 7.18-7.21 (m, 3H), 3.14 (q, J = 7.63 Hz, 2H), 2.99 (t, J = 7.48 Hz, 2H), 2.70 (t, J = 7.63 Hz, 2H), 1.91-1.96 (m, 2H), 1.75- 1.81 (m, 2H), 1.32 (t, J = 7.63 Hz, 3H) 22 4-[5-(4-Phenylbutyl)-1,2,4- oxadiazol-3- yl]benzaldehyde

Intermediate 13 ¹H NMR (600 MHz, CDCl₃) δ 10.09 (s, 1H), 8.25 (d, J = 8.22 Hz, 2H), 8.00 (d, J = 8.22 Hz, 2H), 7.27-7.31 (m, 2H), 7.18- 7.21 (m, 3H), 3.00 (t, J = 7.48 Hz, 2H), 2.70 (t, J = 7.63 Hz, 2H), 1.94 (qd, J = 7.48, 7.68 Hz, 2H), 1.78 (quin, J = 7.70 Hz, 2H) 23 4-[5-(5-Phenylpentyl)- 1,2,4-oxadiazol-3- yl]benzaldehyde

Intermediate 14 ¹H NMR (600 MHz, CDCl₃) δ 10.09 (s, 1H), 8.25 (d, J = 8.22 Hz, 2H), 7.99 (d, J = 8.22 Hz, 2H). 7.25-7.29 (m, 2H), 7.16- 7.19 (m, 3H), 2.96 (t, J = 7.63 Hz, 2H), 2.64 (t, J = 7.63 Hz, 2H), 1.92 (quin, J = 7.70 Hz, 2H), 1.71 (dt, J = 7.67, 15.48 Hz, 2H), 1.46-1.51 (m, 2H) 24 4-[5-(3-Phenylpropyl)- 1,2,4-oxadiazol-3- yl]benzaldehyde

Intermediate 15 ¹H NMR (600 MHz, CDCl₃) δ 10.08 (s, 1H), 8.25 (d, J = 8.51 Hz, 2H), 7.99 (d, J = 8.22 Hz, 2H), 7.29-7.32 (m, 2H), 7.20- 7.23 (m, 3H), 2.97 (t, J = 7.63 Hz, 2H), 2.78 (t, J = 7.48 Hz, 2H), 2.23 (quin, J = 7.56 Hz, 2H)

Example 8 Compound 1 [3-({2-Ethyl-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid

To a solution of Intermediate 21 (190 mg, 0.56 mmol) and (3-aminopropyl) phosphonic acid (79 mg) in methanol (5 mL) was added tetrabutylammonium hydroxide (1M in MeOH, 0.56 mL). The reaction mixture was heated to 50° C. for 1 h with stirring, cooled to RT, then sodium borohydride (32 mg, 0.85 mmol) was added. After the reaction mixture was stirred at RT for 3 h, the mixture was concentrated and purified by MPLC (0-100% methanol in ethyl acetate) to give 159 mg of the desired product as a colorless solid.

¹H NMR (600 MHz, CD₃OD) δ ppm 8.04 (s, 1H), 7.98 (dd, J=1.47, 7.92 Hz, 1H), 7.59 (d, J=7.92 Hz, 1H), 7.25 (t, J=7.63 Hz, 2H), 7.19 (d, J=7.04 Hz, 2H), 7.15 (t, J=7.30 Hz, 1H), 4.34 (s, 2H), 3.28 (t, J=7.34 Hz, 2H), 3.02 (t, J=7.48 Hz, 2H), 2.86 (q, J=7.53 Hz, 2H), 2.70 (t, J=7.63 Hz, 2H), 2.08 (dquin, J=7.63, 15.26 Hz, 2H), 1.90 (sxt, J=7.90 Hz, 2H), 1.86 (t, J=7.63 Hz, 2H), 1.74-1.80 (m, 2H), 1.32 (t, J=7.48 Hz, 3H).

Compounds 2 through 7 were prepared from the corresponding starting materials, in a similar manner to the procedure described in Example 8 for Compound 1. The results are tabulated below in Table 6.

TABLE 6 Comp IUPAC name Starting No. Structure materials ¹H NMR δ (ppm) 2 [3-({3-Fluoro-4-[5-(4- phenylbutyl)-1,2,4-oxadiazol-3- yl]benzyl}amino)propyl] phosphonic acid

Intermediate 18 ¹H NMR (600 MHz, CD₃OD) δ 8.14 (t, J = 7.30 Hz, 1H), 7.47- 7.50 (m, 2H), 7.25 (t, J = 7.00 Hz, 2H), 7.19 (dd, J = 0.88, 7.92 Hz, 2H), 7.13- 7.17 (m, 1H), 4.31 (s, 2H), 3.22 (t, J = 7.30 Hz, 2H), 3.04 (t, J = 7.48 Hz, 2H), 2.69 (t, J = 7.63 Hz, 2H), 2.05 (tdd, J = 7.48, 7.63, 15.19 Hz, 2H), 1.86-1.94 (m, 2H), 1.84 (dt, J = 7.48, 18.49 Hz, 2H), 1.74- 1.79 (m, 2H) 3 [3-({3-Bromo-4-[5-(4- phenylbutyl)-1,2,4-oxadiazol-3- yl]benzyl}amino)propyl] phosphonic acid

Intermediate 19 ¹H NMR (600 MHz, CD₃OD) δ 7.97 (d, J = 1.76 Hz, 1H), 7.87 (d, J = 7.92 Hz, 1H), 7.62 (dd, J = 1.76, 7.92 Hz, 1H), 7.23- 7.27 (m, 2H), 7.19 (d, J = 7.04 Hz, 2H), 7.15 (t, J = 7.00 Hz, 1H), 4.29 (s, 2H), 3.21 (t, J = 7.90 Hz, 2H), 3.05 (t, J = 7.34 Hz, 2H), 2.69 (t, J = 7.48 Hz, 2H), 2.04 (tt, J =7.52, 15.22 Hz, 2H), 1.90 (quin, J = 7.56 Hz, 2H), 1.84 (dt, J = 7.59, 18.56 Hz, 2H), 1.77 (quin, J = 7.63 Hz, 2H) 4 [3-({4-[5-(4-Phenylbutyl)-1,2,4- oxadiazol-3- yl]benzyl}amino)propyl] phosphonic acid

Intermediate 22 ¹H NMR (600 MHz, CD₃OD) δ 8.11 (d, J = 8.22 Hz, 2H), 7.65 (d, J = 8.51 Hz, 2H), 7.23-7.26 (m, 2H), 7.19 (d, J = 7.04 Hz, 2H), 7.13-7.16 (m, 1H), 4.22 (s, 2H), 3.16 (t, J = 6.16 Hz, 2H), 3.01 (t, J = 7.63 Hz, 2H), 2.69 (t, J = 7.63 Hz, 2H), 2.00 (td, J = 6.75, 12.91 Hz, 2H), 1.89 (ddd, J = 7.34,7.48, 15.11 Hz, 2H), 1.69-1.79 (m, 4H) 5 3-({4-[5-(3-Phenylpropyl)-1,2,4- oxadiazol-3- yl]benzyl}amino)propyl] phosphonic acid

Intermediate 24 ¹H NMR (600 MHz, CD₃OD) δ 8.15 (dd, J = 0.88, 7.63 Hz, 2H), 7.65 (d, J = 7.04 Hz, 2H), 7.28 (t, J = 7.63 Hz, 2H), 7.23 (d, J = 7.63 Hz, 2H), 7.16-7.19 (m, 1H), 4.29 (s, 2H), 3.21 (t, J = 7.63 Hz, 2H), 2.99 (t, J = 7.48 Hz, 2H), 2.77 (t, J = 7.34 Hz, 2H), 2.20 (quin, J = 7.41 Hz, 2H), 2.05 (tt, J = 7.48,15.11 Hz, 2H), 1.82-1.88 (m, 2H) 6 [3-({4-[5-(5-Phenylpentyl)-1,2,4- oxadiazol-3- yl]benzyl}amino)propyl] phosphonic acid

Intermediate 23 ¹H NMR (600 MHz, CD₃OD) δ 8.15 (d, J = 8.22 Hz, 2H), 7.65 (d, J = 8.22 Hz, 2H), 7.20-7.24 (m, 2H), 7.16 (d, J = 7.04 Hz, 2H), 7.12 (t, J= 7.92 Hz, 1H), 4.29 (s, 2H), 3.22 (t, J = 7.63 Hz, 2H), 2.99 (t, J = 7.48 Hz, 2H), 2.64 (t, J = 7.63 Hz, 2H), 2.07 (tt, J = 7.52, 15.22 Hz, 2H), 1.83-1.94 (m, 4H), 1.70 (dq, J = 7.58, 7.78 Hz, 2H), 1.47 (ddt, J = 7.59, 7.70, 7.92 Hz, 2H) 7 [3-({3-(2-Furyl)-4-[5-(4- phenylbutyl)1,2,4-oxadiazol-3- yl]benzyl}amino)propyl] phosphonic acid

Intermediate 20 ¹H NMR (600 MHz, CD₃OD) δ 7.95 (d, J = 1.76 Hz, 1H), 7.67 (d, J = 7.92 Hz, 1H), 7.56 (dd, J = 1.76, 7.92 Hz, 1H), 7.39 (d, J = 1.17 Hz, 1H), 7.24-7.27 (m, 2H), 7.14-7.19 (m, 3H), 6.38-6.41 (m, 2H), 4.33 (s, 2H), 3.23 (t, J = 7.60 Hz, 2H), 3.00 (t, J = 7.34 Hz, 2H), 2.67 (t, J = 7.63 Hz, 2H), 2.05 (tdd, J = 7.63, 7.78, 15.19 Hz, 2H), 1.82-1.88 (m, 4H), 1.69-1.76 (m, 2H)

Example 9 Biological Data

Compounds were synthesized and tested for S1P1 activity using the GTP γ³⁵5 binding assay. These compounds may be assessed for their ability to activate or block activation of the human S1P1 receptor in cells stably expressing the S1P1 receptor.

GTP γ³⁵5 binding was measured in the medium containing (mM) HEPES 25, pH 7.4, MgCl₂ 10, NaCl 100, dithitothreitol 0.5, digitonin 0.003%, 0.2 nM GTP γ³⁵S, and 5 μg membrane protein in a volume of 150 μl. Test compounds were included in the concentration range from 0.08 to 5,000 nM unless indicated otherwise. Membranes were incubated with 100 μM 5′-adenylylimmidodiphosphate for 30 min, and subsequently with 10 μM GDP for 10 min on ice. Drug solutions and membrane were mixed, and then reactions were initiated by adding GTP γ³⁵S and continued for 30 min at 25° C. Reaction mixtures were filtered over Whatman GF/B filters under vacuum, and washed three times with 3 mL of ice-cold buffer (HEPES 25, pH7.4, MgCl₂ 10 and NaCl-100). Filters were dried and mixed with scintillant, and counted for ³⁵S activity using a 83-counter. Agonist-induced GTP γ³⁵S binding was obtained by subtracting that in the absence of agonist. Binding data were analyzed using a non-linear regression method. In case of antagonist assay, the reaction mixture contained 10 nM S1P1 in the presence of test antagonist at concentrations ranging from 0.08 to 5000 nM. Table 7 shows activity potency: S1P1 receptor from GTP γ³⁵S: nM, (EC₅₀).

TABLE 7 S1P1 IUPAC name EC₅₀ (nM) [3-({2-Ethyl-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3- 79.23 yl]benzyl}amino)propyl]phosphonic acid [3-({4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl} 63.14 amino)propyl]phosphonic acid 3-({4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl} 606.33 amino)propanoic acid [3-({3-Fluoro-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3- 23.85 yl]benzyl}amino)propyl]phosphonic acid [3-({3-(Furan-2-y1)-4-[5-(4-phenylbutyl)-1,2,4- 216.79 oxadiazol-3-yl]benzyl}amino) propyl]phosphonic acid [3-({3-Bromo-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3- 16.9 yl]benzyl}amino) propyl]phosphonic acid 

What is claimed is:
 1. A compound represented by Formula I, its individual enantiomers, individual diastereoisomers, individual tautomers or a pharmaceutically acceptable salt thereof

wherein: R¹ is substituted or unsubstituted C₆₋₁₀ aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted C₅₋₈ cycloalkyl, substituted or unsubstituted C₅₋₈ cycloalkenyl; R² is hydrogen, —OC₁₋₃ alkyl or substituted or unsubstituted C₁₋₃ alkyl; R³ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁰ or hydroxyl; R⁴ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁰ or hydroxyl; R⁵ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁰ or hydroxyl or substituted or unsubstituted heterocycle; R⁶ is hydrogen, halogen, substituted or unsubstituted C₁₋₃ alkyl, C(O)R¹⁰ or hydroxyl or substituted or unsubstituted heterocycle; R⁷ is hydrogen, —OC₁₋₃ alkyl or substituted or unsubstituted C₁₋₃ alkyl; R⁸ is H or C₁₋₃ alkyl; R⁹ is PO₃H₂, —P(O)MeOH or —P(O)(H)OH; R¹⁰ is H or C₁₋₃ alkyl; a is 2 or 3; b is 1, 2 or 3; c is 1, 2, 3, 4, 5 or
 6. 2. A compound according to claim 1 selected from: [3-({3-(Furan-2-yl)-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino) propyl]phosphonic acid; [3-({3-Bromo-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino) propyl]phosphonic acid; [3-({3-Fluoro-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid; [3-({4-[5-(5-Phenylpentyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid; [3-({4-[5-(3-Phenylpropyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid; and [3-({4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid.
 3. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable adjuvant, diluent or carrier.
 4. A pharmaceutical composition according to claim 3 wherein the compound is selected from: [3-({3-(Furan-2-yl)-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino) propyl]phosphonic acid; [3-({3-Bromo-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid; [3-({3-Fluoro-4-[5-(4-phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid; [3-({4-[5-(5-Phenylpentyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid; [3-({4-[5-(3-Phenylpropyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid; and [3-({4-[5-(4-Phenylbutyl)-1,2,4-oxadiazol-3-yl]benzyl}amino)propyl]phosphonic acid. 